Did Gilead Sciences' Sales Soar in Q4?
Gilead Sciences' fourth quarter and 2015 sales may benefit from an expanding number of people demanding hepatitis C treatment.
1 Big Loser in the Slugfest Between AbbVie and Gilead Sciences
It's a heavyweight hep-C bout between AbbVie and Gilead Sciences. Who is losing?
Which Big Biotech Will Soar in 2015?
Motley Fool contributors think that Gilead Sciences, Biogen Idec, and Celgene Corp could be top performers in 2015.